Russell Investments Group Ltd. Sells 18,162 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Russell Investments Group Ltd. cut its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 71.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,212 shares of the company's stock after selling 18,162 shares during the period. Russell Investments Group Ltd.'s holdings in Castle Biosciences were worth $192,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Wellington Management Group LLP acquired a new position in Castle Biosciences during the fourth quarter valued at $19,244,000. Vanguard Group Inc. raised its position in shares of Castle Biosciences by 4.8% during the fourth quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company's stock worth $48,837,000 after purchasing an additional 83,783 shares during the period. Hussman Strategic Advisors Inc. acquired a new stake in Castle Biosciences during the 4th quarter worth approximately $1,959,000. Trexquant Investment LP boosted its stake in Castle Biosciences by 27.5% in the 4th quarter. Trexquant Investment LP now owns 203,571 shares of the company's stock worth $5,425,000 after purchasing an additional 43,947 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Castle Biosciences by 165.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company's stock valued at $1,980,000 after acquiring an additional 43,241 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Castle Biosciences

In other news, Director Daniel Bradbury sold 7,867 shares of the company's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Derek J. Maetzold sold 1,236 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $21.52, for a total value of $26,598.72. Following the transaction, the insider now directly owns 74,627 shares in the company, valued at $1,605,973.04. This represents a 1.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,321 shares of company stock worth $774,644. Corporate insiders own 7.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Robert W. Baird boosted their price objective on Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Stephens reaffirmed an "overweight" rating and issued a $41.00 price objective on shares of Castle Biosciences in a research report on Thursday, January 2nd. Finally, Guggenheim set a $30.00 price objective on Castle Biosciences and gave the company a "buy" rating in a research note on Friday, March 28th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $38.75.

Castle Biosciences Stock Up 0.1 %

Shares of NASDAQ CSTL traded up $0.03 during trading hours on Thursday, hitting $20.08. The stock had a trading volume of 61,027 shares, compared to its average volume of 389,731. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84. The firm's 50-day moving average price is $20.66 and its two-hundred day moving average price is $26.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The company has a market capitalization of $579.06 million, a P/E ratio of 100.46 and a beta of 1.11.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.